JP7555959B2 - Ｊａｋ１選択的キナーゼ阻害剤 - Google Patents

Ｊａｋ１選択的キナーゼ阻害剤 Download PDF

Info

Publication number
JP7555959B2
JP7555959B2 JP2021561927A JP2021561927A JP7555959B2 JP 7555959 B2 JP7555959 B2 JP 7555959B2 JP 2021561927 A JP2021561927 A JP 2021561927A JP 2021561927 A JP2021561927 A JP 2021561927A JP 7555959 B2 JP7555959 B2 JP 7555959B2
Authority
JP
Japan
Prior art keywords
mmol
equiv
amino
methoxy
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021561927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529061A (ja
JPWO2020211839A5 (enExample
Inventor
チ，チャンヘ
ツイ，ホンチュン
ゼン，チンベイ
ヤン，チェンファン
チャン，シャオリン
Original Assignee
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド filed Critical ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Publication of JP2022529061A publication Critical patent/JP2022529061A/ja
Publication of JPWO2020211839A5 publication Critical patent/JPWO2020211839A5/ja
Application granted granted Critical
Publication of JP7555959B2 publication Critical patent/JP7555959B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021561927A 2019-04-19 2020-04-17 Ｊａｋ１選択的キナーゼ阻害剤 Active JP7555959B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019083376 2019-04-19
CNPCT/CN2019/083376 2019-04-19
PCT/CN2020/085338 WO2020211839A1 (en) 2019-04-19 2020-04-17 Jak1 selective kinase inhibitor

Publications (3)

Publication Number Publication Date
JP2022529061A JP2022529061A (ja) 2022-06-16
JPWO2020211839A5 JPWO2020211839A5 (enExample) 2024-07-08
JP7555959B2 true JP7555959B2 (ja) 2024-09-25

Family

ID=72837031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561927A Active JP7555959B2 (ja) 2019-04-19 2020-04-17 Ｊａｋ１選択的キナーゼ阻害剤

Country Status (15)

Country Link
US (1) US20220220096A1 (enExample)
EP (1) EP3956322B1 (enExample)
JP (1) JP7555959B2 (enExample)
KR (1) KR20220003537A (enExample)
CN (1) CN113710664B (enExample)
AR (1) AR118729A1 (enExample)
AU (1) AU2020258619B2 (enExample)
BR (1) BR112021020964A2 (enExample)
CA (1) CA3134174A1 (enExample)
DK (1) DK3956322T3 (enExample)
ES (1) ES3031576T3 (enExample)
MX (1) MX2021012749A (enExample)
PT (1) PT3956322T (enExample)
TW (1) TW202104215A (enExample)
WO (1) WO2020211839A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7613778B2 (ja) * 2020-11-26 2025-01-15 科輝智薬（深▲セン▼）新薬研究中心有限公司 アミド化合物、医薬組成物およびその使用
CN114380806B (zh) * 2022-03-24 2022-06-10 中国药科大学 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用
US12240836B2 (en) * 2022-07-05 2025-03-04 Dong-A St Co., Ltd. Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof
EP4554931A1 (en) * 2022-07-12 2025-05-21 Adama Makhteshim Ltd. Process for preparing substituted benzamides
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134213A1 (en) 2017-01-17 2018-07-26 Astrazeneca Ab Jak1 selective inhibitors
JP2018529770A (ja) 2015-09-25 2018-10-11 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198900B2 (en) * 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
WO2020057669A1 (zh) * 2018-09-21 2020-03-26 上海轶诺药业有限公司 一类具有激酶抑制活性的芳香杂环类化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529770A (ja) 2015-09-25 2018-10-11 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法
WO2018134213A1 (en) 2017-01-17 2018-07-26 Astrazeneca Ab Jak1 selective inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J． Med. Chem.，2020年04月16日，Vol.63，pp.4517-4527

Also Published As

Publication number Publication date
ES3031576T3 (en) 2025-07-09
EP3956322A1 (en) 2022-02-23
US20220220096A1 (en) 2022-07-14
PT3956322T (pt) 2025-06-04
EP3956322B1 (en) 2025-05-14
KR20220003537A (ko) 2022-01-10
WO2020211839A1 (en) 2020-10-22
BR112021020964A2 (pt) 2021-12-14
JP2022529061A (ja) 2022-06-16
CA3134174A1 (en) 2020-10-22
CN113710664A (zh) 2021-11-26
AR118729A1 (es) 2021-10-27
TW202104215A (zh) 2021-02-01
DK3956322T3 (da) 2025-06-16
AU2020258619B2 (en) 2025-10-23
MX2021012749A (es) 2021-11-18
CN113710664B (zh) 2024-01-26
EP3956322A4 (en) 2023-05-03
AU2020258619A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
JP7555959B2 (ja) Ｊａｋ１選択的キナーゼ阻害剤
US10556908B2 (en) Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US20220340581A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
US10047086B2 (en) Imidazopyridines and imidazopyrazines as LSD1 inhibitors
ES2737696T3 (es) Pirazolopiridinas y pirazolopirimidinas
US8575336B2 (en) Indazoles
CA2858447C (en) Tryazolopyridine derivatives as kinase inhibitors
US10590077B2 (en) TRPV4 antagonists
US20240209001A1 (en) Heterocyclic derivatives as janus kinase inhibitors
KR20160015221A (ko) 키나아제 억제제
RU2818002C2 (ru) Селективный ингибитор киназы JAK1
HK40055987A (en) Jak1 selective kinase inhibitor
KR20210149077A (ko) 포스포이노시타이드 3-키나아제 억제제로서 아이소크로멘 유도체
HK40055987B (zh) Jak1选择性激酶抑制剂
US11230547B2 (en) Purine inhibitors of human phosphatidylinositol 3-kinase delta

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240329

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240911

R150 Certificate of patent or registration of utility model

Ref document number: 7555959

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150